Propanc Biopharma shares preclinical pancreatic cancer data and plans Phase 1b trial in early 2027
Propanc Biopharma reported that its investigational candidate PRP achieved more than 90% tumor‑growth inhibition and over a 2.5‑fold increase in median survival in animal models of advanced pancreatic cancer. The therapy holds FDA Orphan Drug Designation and is not limited to RAS‑mutated tumors. The company announced a multicenter, open‑label Phase 1b first‑in‑human study slated for Q1 2027, targeting up to 50 patients with advanced solid tumours. The news lifted the stock 1.51% to $0.49.
Why it matters
The company’s press release notes the stock rose 1.51% to $0.49 after the announcement, indicating short‑term investor interest. The planned Phase 1b trial could provide the first human data on PRP, which may affect future valuation if results are positive.
Key facts
- 1Preclinical data showed more than 90% mean tumour‑growth inhibition versus vehicle. rttnews.com
- 2Median overall survival was extended by more than 2.5‑fold versus controls in animal models. rttnews.com
- 3PRP holds FDA Orphan Drug Designation for pancreatic cancer. rttnews.com
- 4Phase 1b trial is planned for Q1 2027, enrolling up to 50 patients with advanced solid tumours. rttnews.com
- 5PPCB stock closed at $0.49, up 1.51% on the day of the report. rttnews.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.